Nektar Therapeutics (NKTR) Interest Expenses (2010 - 2020)

Nektar Therapeutics' Interest Expenses history runs 11 years deep, the most recent figure standing at $647000.0 for Q2 2020.

• In Q2 2020, Interest Expenses fell 87.63% year-over-year to $647000.0; the TTM figure through Mar 2021 stood at $647000.0 (down 97.1% YoY), while the FY2020 annual figure was $6.9 million, down 67.85% from the prior year.
• Interest Expenses was $647000.0 for Q2 2020 at Nektar Therapeutics, down from $6.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $6.2 million in Q1 2020 to a low of $647000.0 in Q2 2020.
• Historically, Interest Expenses has averaged $5.2 million across 5 years, with a median of $5.4 million in 2018.
• The sharpest annual moves came in 2016 and 2020: Interest Expenses jumped 36.64% in 2016, then sank 87.63% in 2020.
• A 5-year view of Interest Expenses shows it stood at $5.6 million in 2016, then gained by 1.5% to $5.6 million in 2017, then declined by 3.87% to $5.4 million in 2018, then climbed by 0.24% to $5.4 million in 2019, then slumped by 88.08% to $647000.0 in 2020.
• The last three Interest Expenses figures came in at $647000.0 (Q2 2020), $6.2 million (Q1 2020), and $5.4 million (Q4 2019), per Business Quant data.